New Study Shows Rifaximin Significantly Reduced the Number and Length of Hospitalisations in Patients With Overt Hepatic

Publicado 11/06/2019 10:01:24CET

1. Salehi S, Tranah TH, Lim S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019;00:1-7. [] [Last accessed: June 2019] 2. Morgan M. Chapter 8: Hepatic Encephalopathy in Patients with Cirrhosis. In: Dooley JS, Lok A, Burroughs A, Heathcote J, editors. Sherlock's Diseases of the Liver and Biliary System. 12th ed: Blackwell Publishing Ltd; 2011 3. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014; 61(3):642-659 4. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther. 2007 Feb; 25 Suppl 1:11-6 5. Morgan, C.LI et al, Mortality associated with hepatic encephalopathy in patients with severe liver disease, Journal of Hepatology 2014; 60 (Abstract P452): S219

GL/COR/0519/0189, Date of preparation June 2019

Logo -- []

CONTACT: For further information or an interview with Dr. DebbieShawcross, Investigator of the study please contact: Eleni Fistikaki +44(0)1895826227 or +44 (0)7825 389477, Clara Bentham +44 (0)1895 826654 or+44 (0)7734 367883,


Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación